 | |
| Clinical data | |
|---|---|
| Trade names | Bafiertam |
| License data | |
| Routes of administration | By mouth |
| ATC code |
|
| Legal status | |
| Legal status | |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEBI | |
| ChEMBL | |
| ECHA InfoCard | 100.018.557 |
| Chemical and physical data | |
| Formula | C5H6O4 |
| Molar mass | 130.099 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Monomethyl fumarate, sold under the brand name Bafiertam is a medication for the treatment of relapsing forms of multiple sclerosis, to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults.[1] It is taken by mouth.[1]
The most common adverse reactions are flushing, abdominal pain, diarrhea, and nausea.[1]
It was approved for medical use in the United States in April 2020.[2][3]
YouTube Encyclopedic
-
1/5Views:7966859682 9441 090
-
Role of Diroximel Fumarate in Multiple Sclerosis
-
Let's Learn about a New MS Treatment, - with Nurse Practitioner Katrina M. Bawden, MSN, MSCN, NP-C.
-
MS Drug Action
-
Multiple Sclerosis Vlog: Answering Viewers Questions [Part 3]
-
Updates on MS Disease Progression, Symptom Management, New Treatment options and more
Transcription
Pharmacology
Monomethyl fumarate alters the NFE2L2 (Nuclear factor erythroid 2-related factor 2) transcription factor.
NFE2L2 (or NRF2) is a basic leucine zipper (bZIP) protein that regulates the expression of antioxidant proteins that protect against oxidative damage triggered by injury and inflammation. Several drugs that stimulate the NFE2L2 pathway are being studied for treatment of diseases that are caused by oxidative stress.
Two precursors are also approved:
- Dimethyl fumarate (brand name Tecfidera),[4][5]
- Diroximel fumarate (brand name Vumerity),[6] approved by the FDA in October 2019.[7][8][9][10]
Society and culture
Names
Monomethyl fumarate is the international nonproprietary name (INN).[11]
References
- ^ a b c d "Bafiertam- monomethyl fumarate capsule". DailyMed. Retrieved 13 February 2022.
- ^ "Bafiertam: FDA-Approved Drugs". U.S. Food and Drug Administration (FDA). Retrieved 29 April 2020.
- ^ "Drug Approval Package: Bafiertam". U.S. Food and Drug Administration (FDA). 30 November 2020. Retrieved 13 February 2022.
- ^ "Biogen Idec's Tecfidera (Dimethyl Fumarate) Approved in US as a First-Line Oral Treatment for Multiple Sclerosis" (Press release). Biogen Idec. 27 March 2013. Archived from the original on 12 May 2013. Retrieved 4 June 2013.
- ^ "Drug Approval Package: Tecfidera (dimethyl fumarate) Delayed-Release Capsules NDA #204063". U.S. Food and Drug Administration (FDA). 24 December 1999. Retrieved 30 June 2020.
- ^ Matthew Dodson et al., Modulating NRF2 in Disease: Timing Is Everything, Annual Review of Pharmacology and Toxicology, Vol. 59, January 2019, Review in Advance first posted online on September 26, 2018, https://doi.org/10.1146/annurev-pharmtox-010818-021856
- ^ "Vumerity (Previously BIIB098 and ALKS 8700)". Multiple Sclerosis News Today. 1 November 2019. Retrieved 21 February 2020.
- ^ "Biogen and Alkermes Announce FDA Approval of Vumerity (diroximel fumarate) for Multiple Sclerosis". Biogen. Retrieved 21 February 2020.
- ^ "Vumerity- diroximel fumarate capsule". DailyMed. 30 March 2020. Retrieved 30 June 2020.
- ^ "Drug Approval Package: Vumerity". U.S. Food and Drug Administration (FDA). 21 April 2020. Retrieved 30 June 2020.
- ^ World Health Organization (2020). "International nonproprietary names for pharmaceutical substances (INN) : recommended INN: list 80" (PDF). WHO Drug Information. 34 (1): 74.
 | This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it. |
This page was last edited on 20 March 2024, at 04:44